Zobrazeno 1 - 10 of 106 pro vyhledávání: '"Giuseppe Capri"'
1
Akademický článek
The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis
Autor: Leonardo Provenzano, Riccardo Lobefaro, Francesca Ligorio, Emma Zattarin, Luca Zambelli, Caterina Sposetti, Daniele Presti, Giulia Montelatici, Angela Ficchì, Antonia Martinetti, Alessio Arata, Marta Del Vecchio, Claudia Lauria Pantano, Barbara Formisano, Giulia Valeria Bianchi, Giuseppe Capri, Filippo de Braud, Claudio Vernieri, Giovanni Fucà
Publikováno v: Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Advanced triple-negative breast cancer (aTNBC) has a poor prognosis; thus, there is a need to identify novel biomarkers to guide future research and improve clinical outcomes. Objectives: We tested the prognostic ability of an emerging, c
Externí odkaz: https://doaj.org/article/d60a1af664724f99bf39ed7dd7ca1413
Zobrazit plný text záznamu
2
Akademický článek
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin
Autor: Emma Zattarin, Federico Nichetti, Francesca Ligorio, Laura Mazzeo, Riccardo Lobefaro, Giovanni Fucà, Giorgia Peverelli, Andrea Vingiani, Giulia V. Bianchi, Giuseppe Capri, Filippo de Braud, Claudio Vernieri
Publikováno v: Frontiers in Oncology, Vol 12 (2022)
Extramammary Paget disease (EMPD) is a rare form of cutaneous, intraepithelial adenocarcinoma, which typically presents itself as an erythematous plaque originating from apocrine-gland rich regions, such as the vulva, the perianal region, the scrotum
Externí odkaz: https://doaj.org/article/02ed4f0921e249db898877b9b34d54a9
Zobrazit plný text záznamu
3
Akademický článek
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications
Autor: Claudio Vernieri, Francesca Corti, Federico Nichetti, Francesca Ligorio, Sara Manglaviti, Emma Zattarin, Carmen G. Rea, Giuseppe Capri, Giulia V. Bianchi, Filippo de Braud
Publikováno v: Breast Cancer Research, Vol 22, Iss 1, Pp 1-13 (2020)
Abstract Background The PI3K/AKT/mTORC1 axis is implicated in hormone receptor-positive HER2-negative metastatic breast cancer (HR+ HER2− mBC) resistance to anti-estrogen treatments. Based on results of the BOLERO-2 trial, the mTORC1 inhibitor ever
Externí odkaz: https://doaj.org/article/77080a869ea14ceb99f10f131893b8c5
Zobrazit plný text záznamu
4
Akademický článek
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients
Autor: Francesca Ligorio, Luca Zambelli, Achille Bottiglieri, Lorenzo Castagnoli, Emma Zattarin, Riccardo Lobefaro, Arianna Ottini, Andrea Vingiani, Serenella M. Pupa, Giulia V. Bianchi, Giuseppe Capri, Giancarlo Pruneri, Filippo de Braud, Claudio Vernieri
Publikováno v: Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: High body mass index (BMI) has been associated with worse clinical outcomes in patients with early-stage breast cancer (BC), and its negative effects could be mediated by hyperglycemia/diabetes. However, the prognostic impact of high BMI
Externí odkaz: https://doaj.org/article/2aa8042602b54b37a2bf827af9e515c3
Zobrazit plný text záznamu
5
Akademický článek
Antitumor activity and efficacy of shorter longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer: a 10-year, retrospective analysis
Autor: Riccardo Lobefaro, Emma Zattarin, Federico Nichetti, Michele Prisciandaro, Francesca Ligorio, Marta Brambilla, Pierangela Sepe, Francesca Corti, Giorgia Peverelli, Arianna Ottini, Teresa Beninato, Laura Mazzeo, Carmen G. Rea, Gabriella Mariani, Filippo de Braud, Giulia V. Bianchi, Claudio Vernieri, Giuseppe Capri
Publikováno v: Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Neoadjuvant anthracycline-taxane-based chemotherapy (ChT) is a standard of care treatment option for stage II–III breast cancer (BC) patients. However, the optimal duration of neoadjuvant ChT has been poorly investigated so far. Materia
Externí odkaz: https://doaj.org/article/c3073977056545c1a2af193174e6c1be
Zobrazit plný text záznamu
6
Akademický článek
Efficacia della combinazione lapatinib-capecitabina in una paziente con carcinoma mammario HER2-positivo metastatico e con resistenza primaria a due linee di terapia con agenti anti-HER2
Autor: Claudio Vernieri, Pietro Indelicato, Giuseppe Capri
Publikováno v: AboutOpen, Vol 3, Iss 1 (2017)
La sovraespressione dell’oncoproteina HER2 (human epidermal growth factor receptor 2), spesso sostenuta dall’amplificazione del corrispondente oncogene HER2, si verifica in circa il 15-20% dei carcinomi mammari ed è associata a una rapida cresci
Externí odkaz: https://doaj.org/article/6b6d6ffddaf5401eb8d1c5a8cb0e266d
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje